Skip to main content
Caris Life SciencesLinkedIn

Caris Life Sciences starts patient enrollment in a real-world study of its ChromoSeq WGS assay.

Source: Autobound Signal API · 74 signals tracked for Caris Life Sciences · updated

Get Caris Life Sciences' live signals in Claude or ChatGPT, or by API

AskWhat changed at Caris Life Sciences this week? Use Autobound signals for carislifesciences.com.

Source

LinkedInNov 11, 2026
likes
43
comments
0

Post

Caris Life Sciences announced that the first patients have been enrolled in a prospective, real-world observational study evaluating Caris ChromoSeq™, a Whole Genome Sequencing (WGS) assay designed to provide comprehensive genomic characterization of myeloid malignancies through a single integrated workflow. "Oncology has embraced comprehensive molecular profiling, yet patients with myeloid malignancies are often still evaluated through a fragmented testing process that requires multiple assays and workflows. Caris ChromoSeq was developed to challenge that paradigm,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. Learn more: https://ow.ly/jvS85105CR4

linkedin.com/posts/caris-life-sciences_caris-life-sciences-announced-...Read the full source

Extracted by Autobound

From the Signal API record
Signal
LinkedIn

What this signalsCompany posts often show what the team is pushing right now.

More LinkedIn signals at other companies

The full record

From the Signal API record

Topics and mentions

Tags

  • Medical Research
  • Pharmaceuticals

Initiatives

  • patient enrollment in genomic study

Extraction

Detected
Nov 11, 2026
signal_type
linkedin-post-company
signal_subtype
linkedinPost

Use this data

Get every LinkedIn signal for Caris Life Sciences and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Caris Life Sciences this week?”

  2. Send it to your own tools

    The Signal API returns LinkedIn signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full linkedin-post-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/25385455-0197-4e52-a28f-0081d4803d13 returns this record as JSON. POST /v1/companies/enrich returns every signal for carislifesciences.com.

{
  "signal_id": "25385455-0197-4e52-a28f-0081d4803d13",
  "signal_type": "linkedin-post-company",
  "signal_subtype": "linkedinPost",
  "detected_at": "2026-11-11T14:05:07.884+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "tags": [
      "Medical Research",
      "Pharmaceuticals"
    ],
    "summary": "Caris Life Sciences starts patient enrollment in a real-world study of its ChromoSeq WGS assay.",
    "post_url": "https://www.linkedin.com/posts/caris-life-sciences_caris-life-sciences-announced-that-the-first-activity-7526283877070307328-yjEV",
    "num_likes": 43,
    "post_text": "Caris Life Sciences announced that the first patients have been enrolled in a prospective, real-world observational study evaluating Caris ChromoSeq™, a Whole Genome Sequencing (WGS) assay designed to provide comprehensive genomic characterization of myeloid malignancies through a single integrated workflow.\n \n\"Oncology has embraced comprehensive molecular profiling, yet patients with myeloid malignancies are often still evaluated through a fragmented testing process that requires multiple assays and workflows. Caris ChromoSeq was developed to challenge that paradigm,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences.\n \nLearn more: https://ow.ly/jvS85105CR4",
    "initiatives": [
      {
        "topic": "patient enrollment in genomic study",
        "urgency": 0.6
      }
    ],
    "posted_date": "2026-11-11T14:05:07.884Z",
    "num_comments": 0
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.